title: Humoral immune response to human cytomegalovirus in patients undergoing percutaneous transluminal coronary angioplasty.
abstract: Possible causal relations between prior human cytomegalovirus (HCMV) infection and atherosclerosis and between HCMV reactivation and restenosis after coronary angioplasty have been suggested. We investigated patterns of antibodies directed to HCMV in 112 patients undergoing percutaneous transluminal coronary angioplasty (PTCA) and in a group of sex- and age-matched controls (blood donors without evidence of atherosclerosis). Levels of antibodies to HCMV were measured by enzyme-linked immunosorbent assay (ELISA) of serum samples drawn before and 5 weeks after PTCA. To further differentiate the humoral immune response, we specifically tested antibody reactivity towards four single HCMV proteins (IE2, p52, pp150, and pp65) by recombinant ELISAs. We found that 73% of PTCA patients and 69% of sex- and age-matched controls were seropositive for HCMV (odds ratio, 1.2 [not significant]). The corresponding odds ratios for matched pairs ranged in the recombinant ELISAs from 1.2 to 1.4. Patients had more often high titers of anti-HCMV antibodies (11 versus 4%; odds ratio = 3.3 [0.9 to 15.2]; P = 0.052) and high titers of anti-pp150 antibodies (13 versus 4%; odds ratio = 6.0 [1.3 to 38.8]; P = 0.008). Anti-HCMV immunoglobulin M antibodies were not detected in any patient. There was no evidence of acute HCMV reactivation after PTCA, since the titers of antibodies to the investigated recombinant proteins did not increase at 5 weeks after PTCA. Our results show a limited association between prior HCMV infection and coronary artery disease. We infer that positive anti-HCMV titers are not a major risk factor at the time of disease manifestation. However, this study cannot rule out a possible role of HCMV at earlier stages of the atherosclerotic process. Recombinant ELISAs provide a valuable tool for investigating the antiviral immune response.
authors.affiliation: Department of Clinical Immunology, University of Groningen, 9713 GZ Groningen, The Netherlands. andreas.tiran@kfunigratz.ac.at
authors.forename: A
authors.initials: A
authors.lastname: Tiran
authors.forename: R A
authors.initials: RA
authors.lastname: Tio
authors.forename: E
authors.initials: E
authors.lastname: Oostenveld
authors.forename: M C
authors.initials: MC
authors.lastname: Harmsen
authors.forename: B
authors.initials: B
authors.lastname: Tiran
authors.forename: P
authors.initials: P
authors.lastname: Den Heijer
authors.forename: S H
authors.initials: SH
authors.lastname: Monnink
authors.forename: M M
authors.initials: MM
authors.lastname: Wilders-Truschnig
authors.forename: T H
authors.initials: TH
authors.lastname: The
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects*; D000914:Antibodies, Viral / Q000097:blood*; D000956:Antigens, Viral / Q000235:genetics; D001161:Arteriosclerosis / Q000209:etiology* / Q000628:therapy* / Q000821:virology; D016022:Case-Control Studies; D003587:Cytomegalovirus / Q000235:genetics / Q000276:immunology* / Q000472:pathogenicity*; D003586:Cytomegalovirus Infections / Q000150:complications* / Q000276:immunology; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011994:Recombinant Proteins / Q000235:genetics / Q000276:immunology; D012008:Recurrence; D012307:Risk Factors; D013997:Time Factors
chemical_list: D000914:Antibodies, Viral; D000956:Antigens, Viral; D011994:Recombinant Proteins